Matching articles for "Issue 1333"
Issue 1333 · March 8, 2010
Rosiglitazone (Avandia) Revisited

The cardiovascular safety of the thiazolidinedione rosiglitazone ( Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19,…

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):17
The cardiovascular safety of the thiazolidinedione rosiglitazone ( Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).
Issue 1333 · March 8, 2010 Free
Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high…

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):17-9
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H 2 -receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol ( Cytotec , and others), and antibiotics to eradicate H. pylori . Click here to view the free full article.
Issue 1333 · March 8, 2010
Hyperbaric Oxygen Therapy for Refractory Wounds

Hyperbaric oxygen (HBO 2 ) therapy, breathing 100% O 2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):19-20
Hyperbaric oxygen (HBO 2 ) therapy, breathing 100% O 2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.
Issue 1333 · March 8, 2010 Free
Addendum: Cost of Ustekinumab (Stelara)

In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):20
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.